Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening.

Inclusions comprised of fibrils of the microtubule- (MT-) associated protein tau are found in the brains of those with Alzheimer's disease (AD) and other neurodegenerative tauopathies. The pathology that is observed in these diseases is believed to result from the formation of toxic tau oligomers or fibrils and/or from the loss of normal tau function due to its sequestration into insoluble deposits. Hence, small molecules that prevent tau oligomerization and/or fibrillization might have therapeutic value. Indeed, examples of such compounds have been published, but nearly all have properties that render them unsuitable as drug candidates. For these reasons, we conducted quantitative high-throughput screening (qHTS) of approximately 292000 compounds to identify drug-like inhibitors of tau assembly. The fibrillization of a truncated tau fragment that contains four MT-binding domains was monitored in an assay that employed complementary thioflavin T fluorescence and fluorescence polarization methods. Previously described classes of inhibitors as well as new scaffolds were identified, including novel aminothienopyridazines (ATPZs). A number of ATPZ analogues were synthesized, and structure-activity relationships were defined. Further characterization of representative ATPZ compounds showed they do not interfere with tau-mediated MT assembly, and they are significantly more effective at preventing the fibrillization of tau than the Abeta(1-42) peptide which forms AD senile plaques. Thus, the ATPZ molecules described here represent a novel class of tau assembly inhibitors that merit further development for testing in animal models of AD-like tau pathology.

[1]  K. Kosik,et al.  Structure and novel exons of the human tau gene. , 1992, Biochemistry.

[2]  E. Mandelkow,et al.  Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. , 2000, Biochemistry.

[3]  M. Goedert Tau gene mutations and their effects , 2005, Movement disorders : official journal of the Movement Disorder Society.

[4]  Adam Yasgar,et al.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Jesús Avila,et al.  Glycogen synthase kinase 3: a drug target for CNS therapies , 2004, Journal of neurochemistry.

[6]  Sam Michael,et al.  A robotic platform for quantitative high-throughput screening. , 2008, Assay and drug development technologies.

[7]  J. Trojanowski,et al.  Microtubule-stabilising drugs for therapy of Alzheimer’s disease and other neurodegenerative disorders with axonal transport impairments , 2005, Expert opinion on pharmacotherapy.

[8]  J. Trojanowski,et al.  Tau and axonopathy in neurodegenerative disorders , 2002, NeuroMolecular Medicine.

[9]  U. Wagner,et al.  Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. , 1996, Journal of cell science.

[10]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[11]  Peter Wipf,et al.  Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. , 2008, Assay and drug development technologies.

[12]  Takeshi Iwatsubo,et al.  Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins* , 2005, Journal of Biological Chemistry.

[13]  John Q Trojanowski,et al.  Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. , 2006, Journal of Alzheimer's disease : JAD.

[14]  A. Hyman,et al.  Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. , 1992, Molecular biology of the cell.

[15]  R. Keast,et al.  Phytochemistry: Ibuprofen-like activity in extra-virgin olive oil , 2005, Nature.

[16]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[17]  Wenwei Huang,et al.  Differentiating Alzheimer disease-associated aggregates with small molecules , 2007, Neurobiology of Disease.

[18]  Chi Li,et al.  Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[20]  M. Kirschner,et al.  Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly. , 1977, Journal of molecular biology.

[21]  M. Kirschner,et al.  Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. , 1977, Journal of molecular biology.

[22]  J. Trojanowski,et al.  Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors. , 2007, Biochemistry.

[23]  Michael P. Mazanetz,et al.  Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases , 2007, Nature Reviews Drug Discovery.

[24]  J. Trojanowski,et al.  Selective Destruction of Stable Microtubules and Axons by Inhibitors of Protein Serine/Threonine Phosphatases in Cultured Human Neurons (NT2N Cells) , 1997, The Journal of Neuroscience.

[25]  Alexandra Flemming,et al.  Infectious disease: Unravelling SARS lethality , 2005, Nature Reviews Drug Discovery.

[26]  J. Wells,et al.  Malonate-assisted purification of human caspases. , 2005, Protein expression and purification.

[27]  C. Chirita,et al.  Anionic Micelles and Vesicles Induce Tau Fibrillization in Vitro* , 2003, Journal of Biological Chemistry.

[28]  Paul Greengard,et al.  Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies , 2007, Proceedings of the National Academy of Sciences.

[29]  Boris Schmidt,et al.  Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. , 2007, Biochemistry.

[30]  John Q Trojanowski,et al.  Transgenic animal models of tauopathies. , 2005, Biochimica et biophysica acta.

[31]  Abnormally phosphorylated tau from Alzheimer disease brain depolymerizes microtubules A. del C. Alonso, I. Grundke-Iqbal and K. Iqbal. New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York 10314 USA , 1994, Neurobiology of Aging.

[32]  R. Crowther,et al.  Cloning and sequencing of the cDNA encoding an isoform of microtubule‐associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. , 1989, The EMBO journal.

[33]  Alejandra del C. Alonso,et al.  Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules , 1996, Nature Medicine.

[34]  E. Mandelkow,et al.  Anthraquinones Inhibit Tau Aggregation and Dissolve Alzheimer's Paired Helical Filaments in Vitro and in Cells* , 2005, Journal of Biological Chemistry.

[35]  J. Trojanowski,et al.  Neurodegenerative tauopathies. , 2001, Annual review of neuroscience.

[36]  J. Kuret,et al.  Pseudophosphorylation and Glycation of Tau Protein Enhance but Do Not Trigger Fibrillization in Vitro* , 2004, Journal of Biological Chemistry.

[37]  C. Lipinski Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[38]  E. Mandelkow,et al.  Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. , 2007, Angewandte Chemie.

[39]  M. Roth,et al.  Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  E. Mandelkow,et al.  Domains of tau protein and interactions with microtubules. , 1994, Biochemistry.

[41]  Michael Cory,et al.  Expression, preparation, and high-throughput screening of caspase-8: discovery of redox-based and steroid diacid inhibition. , 2002, Archives of biochemistry and biophysics.

[42]  R. Crowther,et al.  Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans , 1996, Nature.

[43]  D. Wilson,et al.  Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. , 1997, The American journal of pathology.

[44]  G. K. Wilcock,et al.  Plaques, tangles and dementia A quantitative study , 1982, Journal of the Neurological Sciences.

[45]  Michel Goedert,et al.  Mutations causing neurodegenerative tauopathies. , 2005, Biochimica et biophysica acta.

[46]  John Q Trojanowski,et al.  Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. , 2008, Journal of Alzheimer's disease : JAD.

[47]  J. Agar,et al.  Fitting neurological protein aggregation kinetic data via a 2-step, minimal/"Ockham's razor" model: the Finke-Watzky mechanism of nucleation followed by autocatalytic surface growth. , 2008, Biochemistry.

[48]  V. Lee,et al.  Characterization of two VQIXXK motifs for tau fibrillization in vitro. , 2006, Biochemistry.

[49]  John Q. Trojanowski,et al.  Abnormal tau phosphorylation at Ser396 in alzheimer's disease recapitulates development and contributes to reduced microtubule binding , 1993, Neuron.

[50]  Cam Patterson,et al.  The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. , 2007, The Journal of clinical investigation.

[51]  John X. Morris,et al.  Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. , 1998, Science.

[52]  John Q Trojanowski,et al.  High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. , 2007, Biochemical and biophysical research communications.

[53]  Bradley T. Hyman,et al.  Distribution of Alzheimer‐type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease , 1992, Neurology.

[54]  J. Trojanowski,et al.  A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114 , 2003, Journal of neurochemistry.

[55]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[56]  P. Sexton,et al.  2-aminothienopyridazines as novel adenosine A1 receptor allosteric modulators and antagonists. , 2008, Journal of medicinal chemistry.

[57]  P. Greengard,et al.  Pharmacological inhibitors of glycogen synthase kinase 3. , 2004, Trends in pharmacological sciences.

[58]  Brian K Shoichet,et al.  A detergent-based assay for the detection of promiscuous inhibitors , 2006, Nature Protocols.

[59]  S. Ferreira,et al.  Soluble Protein Oligomers as Emerging Toxins in Alzheimer′s and Other Amyloid Diseases , 2007 .